Cosentyx® – Secukinumab Injection

Cosentyx® – Secukinumab Injection | U.S.-Manufactured Global Supply Monoclonal Antibody

Product Overview

Cosentyx® (secukinumab) is a fully human IgG1/κ monoclonal antibody that targets interleukin-17A (IL-17A), developed and manufactured by Novartis Pharmaceuticals Corporation in the United States. It is the world’s first approved IL-17A inhibitor, indicated for a broad range of immune-mediated inflammatory diseases including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and others.

The product offered here is part of the official global supply chain and is manufactured in the United States by the originator company. It is intended for international distribution under local regulatory requirements. While the packaging language and labeling may vary based on destination market regulations, the formulation, dosage form, device, and manufacturing quality are identical to the U.S.-marketed version.

Key Features & Advantages

• ✅ U.S.-Manufactured by Novartis Pharmaceuticals
  Original biologic drug made under strict FDA and global cGMP standards.

• ✅ Same Composition as U.S. Version
  Identical formulation, concentration, and delivery system; only packaging language is adapted for local compliance.

• ✅ First-in-Class IL-17A Blocker
  Approved in over 100 countries; extensive real-world safety and efficacy data.

• ✅ Multiple Indications
  Includes moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa (availability and indication vary by region).

• ✅ Global Supply Ready
  Suitable for licensed importers, hospitals, international health systems, and registered distributors.

Product Specifications

• Product Name: Cosentyx® (secukinumab injection)

• Active Ingredient: Secukinumab (recombinant human IgG1 monoclonal antibody)

• Strength / Form: 150 mg/mL or 300 mg/2 mL prefilled syringe / autoinjector

• Administration: Subcutaneous injection

• Manufacturer: Novartis Pharmaceuticals Corporation (USA)

• Packaging: International version with destination-specific labeling; drug content identical to U.S. formulation

• Storage: 2°C–8°C refrigerated; do not freeze

• Shelf Life: Typically 24 months from manufacture

• Supply Category: Original brand biologic; not a biosimilar or generic

Mechanism of Action

Cosentyx® works by selectively binding and neutralizing interleukin-17A (IL-17A), a cytokine that plays a central role in chronic inflammation of the skin, joints, and spine. By blocking IL-17A, secukinumab inhibits inflammatory signaling and reduces the immune system’s abnormal activity.

Clinically, this results in:

• Rapid clearance of psoriatic plaques

• Reduced joint inflammation and long-term structural protection

• Improved spinal mobility and pain control in axial spondyloarthritis

Reference: NIH: Mechanism of Secukinumab

Compliance Statement

This product is manufactured in the United States by Novartis Pharmaceuticals Corporation and is distributed as part of its international supply chain. It is identical in composition and manufacturing standard to the U.S.-market version, with only packaging and labeling adapted for regulatory compliance in export markets. This product is intended for lawful use by licensed importers, medical institutions, and distribution partners. All recipients are responsible for ensuring compliance with local pharmaceutical laws and regulations.

Tags / Keywords

Cosentyx International Version, Secukinumab Global Supply, IL-17A Monoclonal Antibody, Novartis Biologic, U.S.-Manufactured MAb, Autoimmune Biologic Therapy, Psoriasis Injection, Ankylosing Spondylitis Treatment, Global Distribution Biologics, Non-Biosimilar Secukinumab